IDWeek 2026] Infectious Disease Advisor | Novel doravirine/islatravir yields similar patient-reported outcomes in HIV-1
Treatment with DOR/ISL or BIC/FTC/TAF similarly improves health status in previously untreated adults with HIV-1.
2 sourcesUpdated 1m ago
![IDWeek 2026] Infectious Disease Advisor | Novel doravirine/islatravir yields similar patient-reported outcomes in HIV-1](https://www.infectiousdiseaseadvisor.com/wp-content/uploads/sites/16/2026/10/IDWeek-2026.png)
Coverage across the spectrum
How we rate outletsLeft 0% · 0Center 100% · 2Right 0% · 0
Who's reporting it
Reader Discussion
Loading comments…







